Dodaj do ulubionych

Leki antywirusowe skuteczne w niekt. przypadkach

22.04.07, 05:55
The information about the first study is here:

www.eurekale releases/ 2007-01/sumc- ntf010807. php

And the contact information if you are interested in participating in the
new study is here:

www.vicd. info/clinicaltri al.html

It's only for people who have high levels of EBV and HHV antibodies.

New therapy for chronic fatigue syndrome to be tested at Stanford
STANFORD, Calif. -- A preliminary study suggests there may be hope in the
offing for some sufferers of chronic fatigue syndrome with a new therapy being
tested by researchers at the Stanford University School of Medicine.

José Montoya, MD, associate professor of medicine (infectious diseases), and
postdoctoral scholar Andreas Kogelnik, MD, PhD, have used the drug
valganciclovir - an antiviral often used in treating diseases caused by human
herpes viruses - to treat a small number of CFS patients.

The researchers said they treated 25 patients during the last three years, 21
of whom responded with significant improvement that was sustained even after
going off the medication at the end of the treatment regimen, which usually
lasts six months.

The first patient has now been off the drug for almost three years and has had
no relapses.

A paper describing the first dozen patients Montoya and Kogelnik treated with
the drug was published in the December issue of Journal of Clinical Virology.

"This study is small and preliminary, but potentially very important," said
Anthony Komaroff, MD, professor of medicine at Harvard Medical School, who was
not involved in the study.

"If a randomized trial confirmed the value of this therapy for patients like
the ones studied here, it would be an important landmark in the treatment of
this illness."

Montoya has received a $1.3 million grant from Roche Pharmaceutical, which
manufactures the drug under the brand name Valcyte, to conduct a randomized,
placebo-controlled, double-blind study set to begin this quarter at Stanford.

The study will assess the effectiveness of the drug in treating a subset of
CFS patients.

Montoya is speaking about his efforts at the biannual meeting of the
International Association for Chronic Fatigue Syndrome in Fort Lauderdale on
Jan. 11 and 12.

Chronic fatigue syndrome has baffled doctors and researchers for decades,
because aside from debilitating fatigue, it lacks consistent symptoms.

Although many genetic, infectious, psychiatric and environmental factors have
been proposed as possible causes, none has been nailed down. It was often
derided as "yuppie flu," since it seemed to occur frequently in young
professionals, though the Centers for Disease Control and Prevention says it's
most common in the middle-aged.

But to those suffering from it, CFS is all too real and its effects are
devastating, reducing once-vigorous individuals to the ranks of the bedridden,
with an all-encompassing, painful and sleep-depriving fatigue.

More than 1 million Americans suffer from the disorder, according to the CDC.
The disease often begins with what appears to be routine flulike symptoms, but
then fails to subside completely - resulting in chronic, waxing and waning
debilitation for years.

Valganciclovir is normally used against diseases caused by viruses in the
herpes family, including cytomegalovirus, Epstein-Barr virus and human herpes

These diseases usually affect patients whose immune systems are severely
weakened, such as transplant and cancer patients.

Montoya, who had used the drug in treating such patients for years, decided to
try using it on a CFS patient who came to him in early 2004 with extremely
high levels of antibodies for three of the herpes family viruses in her blood.

At the time, she had been suffering from CFS for five years.

When a virus infects someone, the levels of antibodies cranked out by the
immune system in response typically increase until the virus is overcome, then
slowly diminish over time.

But Montoya's patient had persistently high antibodies for the three viruses.

In addition, the lymph nodes in her neck were significantly enlarged, some up
to eight times their normal size, suggesting her immune system was fighting
some kind of infection, even though a comprehensive evaluation had failed to
point to any infectious cause.

Concerned about the unusual elevations in antibody levels as well as the
swelling of her lymph nodes, Montoya decided to prescribe valganciclovir.

"I thought by giving an antiviral that was effective against herpes viruses
for a relatively long period of time, perhaps we could impact somehow the
inflammation that she had in her lymph nodes," said Montoya.

Within four weeks, the patient's lymph nodes began shrinking. Six weeks later
she phoned Montoya from her home in South America, describing how she was now
exercising, bicycling and going back to work at the company she ran before her

"We were really shocked by this," recalled Montoya.

Of the two dozen patients Montoya and Kogelnik have since treated, the 20 that
responded all had developed CFS after an initial flulike illness, while the
non-responders had suffered no initial flu.

Some of the patients take the drug for more than six months, such as Michael
Manson, whose battle with CFS has lasted more than 18 years.

The former triathlete was stricken with a viral infection a year after his

After trying unsuccessfully to overcome what he thought were lingering effects
of the flu, he had no choice but to drastically curtail all his activities and
eventually stop working.

During his longest period of extreme fatigue, 13 1/2 weeks, Manson said, "My
wife literally thought I was passing away.

I could hear the emotion in her voice as she tried to wake me, but I couldn't
wake up to console her. That was just maddening."

Now in his seventh month of treatment, Manson is able to go backpacking with
his children with no ill after-effects. Prior to starting the treatment,
Manson's three children, ages 9 to 14, had never seen him healthy.

Montoya and Kogelnik emphasized that even if their new clinical trial
validates the use of valganciclovir in treating some CFS patients, the drug
may not be effective in all cases.

In fact, the trial will assess the effectiveness of the medication among a
specific subset of CFS patients; namely, those who have viral-induced
dysfunction of the central nervous system.

"This could be a solution for a subset of patients, but that subset could be
quite large," said Kristin Loomis, executive director of the HHV-6 Foundation,
which has helped fund a significant portion of the preparatory work for the
clinical trial.

"These viruses have been suspected in CFS for decades, but researchers
couldn't prove it because they are so difficult to detect in the blood.
If Montoya's results are confirmed, he will have made a real breakthrough."

"What is desperately needed is the completion of the randomized, double-blind,
placebo-controlled clinical trial that we are about to embark on," Montoya said.

BROADCAST MEDIA CONTACT: M.A. Malone at (650) 723-6912 (

People interested in participating in the clinical trial must live in the San
Francisco Bay Area. More information about the clinical trial is available
online at

Stanford University Medical Center integrates research, medical education and
patient care at its three institutions - Stanford University School of
Medicine, Stanford Hospital & Clinics and Lucile Packard Children's Hospital
at Stanford. For more information, please visit the Web site of the medical
center's Office of Communication & Public Affairs at <a href="
Edytor zaawansowany
  • marta.gora 22.04.07, 13:21
    hehe, specjalistą od leczenie przeciwwirusowego, jest -zdaje się- Geodeta :-)
    Przetestował się trochę, ale i tak wylądował na antybiotykach. Moim skromnym
    zdaniem, jesli jest jakaś przetrwała infekcja wirusowa, to CFS jest to objaw, a
    przyczyny trzeba szukać w układzie odpornościowym. Co z tego, jesli wyruguje
    się z organizmu np. wirusa opryszczki, jesli mozna ją złapac ponownie już tego
    samego dnia?
    "Każde kłamstwo powiedziane 10 razy, za 11 razem staje się prawdą".
  • mirasghoshal 24.05.07, 10:23
    Drogi Panie Arturze,

    Wiem juz cos o tej metodzie leczenia. Valcyte jest drogim lekiem i jest uzywany
    przy przeszczepach. Pol roku leczenia kosztuje ok. 60 000 zl. Na koniec roku
    beda wyniki nastepnej proby tym razem z 30 osobami. Jezeli Pan chce to przesle
    panu artykul z Journal of Virology z tabelami wynikow testow na wirusu i z
    poprawa samopoczucia ludzi po 6 miesiacach leczenia. Wyglada ze jest to bardzo
    dobra metoda, tylko ze narazie jest droga. Jezeli by wiecej ludzi na calym
    swiecie zaczelo brac ten lek to cena by poszla w doj i by sie zaczela masowa
    produkcja. W samych Stanach jest w tej chwili 4 miliony ludzi chorych na ZPZ.
    Jestem w kontakcie z jednym lekarzem ktory jest czescia ekipy Dr. Montoya.


Popularne wątki

Nie pamiętasz hasła

lub ?


Nie masz jeszcze konta? Zarejestruj się

Nakarm Pajacyka